Summary

The oral multikinase inhibitor regorafenib targets multiple pathways involved in tumor development and progression. In the CORRECT study [Grothey A et al. Lancet. 2013], treatment with regorafenib improved overall survival (OS) in patients with metastatic colorectal cancer (mCRC) disease progression after standard therapies (HR, 0.77; 95% CI, 0.64 to 0.94; 1-sided p?=?.0052). This article presents the results from the Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy study [CONCUR; NCT01584830], a trial examining the efficacy and safety of regorafenib in a larger group of Asian patients with mCRC.